Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma

References

• GINA Report, Global Strategy for Asthma Management and Prevention [Internet]. Global Initiative for Asthma; 2016. [cited 2017 Jan 11]. Available from: http://ginasthma.org/gina-reports).
   Google Scholar
• BTS/SIGN British guideline on the management of asthma [Internet]. British Thoracic Society; 2016. [cited 2017 Jan 11] Available from: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma.
   Google Scholar
• Busse WW, Pedersen S, Pauwels RA, et al. The inhaled steroid Treatment as Regular Therapy in early asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2008;121(5):1167–1174.
   PubMed Web of Science ®Google Scholar
• Selroos O, Pietinalho A, Lofroos AB, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108(5):1228–1234.
   PubMed Web of Science ®Google Scholar
• Selroos O. Effect of disease duration on dose-response of inhaled budesonide in asthma. Respir Med. 2008;102(7):1065–1072.
   PubMed Web of Science ®Google Scholar
• Rank MA, Hagan JB, Park MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;131(3):724–729.
   PubMed Web of Science ®Google Scholar
• Chiu S-F, Kelton CML, Guo JJ, et al. Utilization, spending, and price trends for short- and long-acting beta-agonists and inhaled corticosteroids in the medicaid program, 1991–2010. Am Health Drug Benefits. 2011;4(3):140–149.
   PubMedGoogle Scholar
• Laustsen G. Ciclesonide (Alvesco) approved to treat asthma. Nurse Pract. 2008;33(7):11–13.
   PubMedGoogle Scholar
• Adams N, Bestall JM, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma. Cochrane Database Syst Rev. 2002;(1):Cd002310.
   PubMedGoogle Scholar
• Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102(4 Pt 2):S36–51.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Barnes PJ, eds. New drugs for asthma, allergy and COPD. Basel, Switzerland: Karger. 2001.
   Google Scholar
• Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91(Suppl A):22–28.
   PubMed Web of Science ®Google Scholar
• Busse et al. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5Suppl):S94–138.
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 0):S65–S87.
   PubMed Web of Science ®Google Scholar
• Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol. 2012;129(3 0):S24–S33.
   PubMed Web of Science ®Google Scholar
• Kannisto S, Korppi M, Arikoski P, et al. Biochemical markers of bone metabolism in relation to adrenocortical and growth suppression during the initiation phase of inhaled steroid therapy. Pediatr Res. 2002;52(2):258–262.
   PubMed Web of Science ®Google Scholar
• Kannisto S, Korppi M, Remes K, et al. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2001;86(10):4908–4912.
   PubMed Web of Science ®Google Scholar
• Kannisto S, Voutilainen R, Remes K, et al. Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. Pediatr Allergy Immunol. 2002;13(1):24–30.
   PubMed Web of Science ®Google Scholar
• Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(−1)) versus HFA-fluticasone propionate (1000 microg day(−1)) in patients with asthma. Respir Med. 2001;95(3):212–220.
   PubMed Web of Science ®Google Scholar
• Ayres JG, Bateman ED, Lundback B, et al. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J. 1995;8(4):579–586.
   PubMed Web of Science ®Google Scholar
• Barnes NC, Marone G, Di Maria GU, et al. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 1993;6(6):877–885.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Linnhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther. 2008;21(2):264–275.
   PubMed Web of Science ®Google Scholar
• Bootsma GP, Dekhuijzen PN, Festen J, et al. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax. 1995;50(10):1044–1050.
   PubMed Web of Science ®Google Scholar
• Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med. 2007;101(8):1677–1686.
   PubMed Web of Science ®Google Scholar
• Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther. 2006;19(6):404–412.
   PubMed Web of Science ®Google Scholar
• Currie GP, Fowler SJ, Wilson AM, et al. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax. 2002;57(10):865–868.
   PubMed Web of Science ®Google Scholar
• Dahl R, Engelstatter R, Trebas-Pietras E, et al. A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma. Respir Med. 2010;104(8):1121–1130.
   PubMed Web of Science ®Google Scholar
• Dahl R, Lundback B, Malo JL, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest. 1993;104(5):1352–1358.
   PubMed Web of Science ®Google Scholar
• Derom E, van de Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5ʹmonophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005;18(5):328–336.
   PubMed Web of Science ®Google Scholar
• Derom E, van Schoor J, Verhaeghe W, et al. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med. 1999;160(1):157–161.
   PubMed Web of Science ®Google Scholar
• Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993;48(8):817–823.
   PubMed Web of Science ®Google Scholar
• Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol. 2001;86(5):575–582.
   PubMed Web of Science ®Google Scholar
• Harrison TW, Wisniewski A, Honour J, et al. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax. 2001;56(3):186–191.
   PubMed Web of Science ®Google Scholar
• Heinig JH, Boulet LP, Croonenborghs L, et al. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respir Med. 1999;93(9):613–620.
   PubMed Web of Science ®Google Scholar
• Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int. 2010;59(1):59–66.
   PubMedGoogle Scholar
• Hughes JA, Conry BG, Male SM, et al. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax. 1999;54(3):223–229.
   PubMed Web of Science ®Google Scholar
• Knox A, Langan J, Martinot JB, et al. Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma. Curr Med Res Opin. 2007;23(10):2387–2394.
   PubMed Web of Science ®Google Scholar
• Kuna P, Joubert JR, Greefhorst LA, et al. A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Clin Ther. 2003;25(8):2182–2197.
   PubMed Web of Science ®Google Scholar
• Leblanc P, Mink S, Keistinen T, et al. A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma. Allergy. 1994;49(5):380–385.
   PubMed Web of Science ®Google Scholar
• Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest. 2005;127(3):851–860.
   PubMed Web of Science ®Google Scholar
• Lee DK, Haggart K, Currie GP, et al. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol. 2004;58(1):26–33.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. 2005;94(4):465–472.
   PubMed Web of Science ®Google Scholar
• Lorentzen KA, van Helmond JL, Bauer K, et al. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. Respir Med. 1996;90(10):609–617.
   PubMed Web of Science ®Google Scholar
• Lundback B, Alexander M, Day J, et al. Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler. Respir Med. 1993;87(8):609–620.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. J Asthma. 2007;44(7):555–563.
   PubMed Web of Science ®Google Scholar
• Malo JL, Cartier A, Ghezzo H, et al. Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. Eur Respir J. 1999;13(5):993–998.
   PubMed Web of Science ®Google Scholar
• Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000;162(6):2053–2057.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Yernault JC, Demedts MG, et al. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med. 1998;157(3 Pt 1):827–832.
   PubMed Web of Science ®Google Scholar
• Raphael GD, Lanier RQ, Baker J, et al. A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. J Allergy Clin Immunol. 1999;103(5 Pt 1):796–803.
   PubMed Web of Science ®Google Scholar
• Ringdal N, Lundback B, Alton M, et al. Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients. Respir Med. 2000;94(5):482–489.
   PubMed Web of Science ®Google Scholar
• Szefler S, Rohatagi S, Williams J, et al. a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest. 2005;128(3):1104–1114.
   PubMed Web of Science ®Google Scholar
• Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, et al. Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respir Med. 2006;100(9):1651–1656.
   PubMed Web of Science ®Google Scholar
• Acun C, Tomac N, Ermis B, et al. Effects of inhaled corticosteroids on growth in asthmatic children: a comparison of fluticasone propionate with budesonide. Allergy Asthma Proc. 2005;26(3):204–206.
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatr Allergy Immunol. 2010;21(1 Pt 2):e199–205.
   PubMed Web of Science ®Google Scholar
• Anhoj J, Bisgaard AM, Bisgaard H. Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics. 2002;109(3):E40.
   PubMed Web of Science ®Google Scholar
• Cetinkaya F, Kayiran P, Memioglu N, et al. Effects of nebulized corticosteroids therapy on hypothalamic-pituitary-adrenal axis in young children with recurrent or persistent wheeze. Pediatr Allergy Immunol. 2008;19(8):773–776.
   PubMed Web of Science ®Google Scholar
• de Benedictis FM, Del Giudice MM, Vetrella M, et al. Nebulized fluticasone propionate vs. budesonide as adjunctive treatment in children with asthma exacerbation. J Asthma. 2005;42(5):331–336.
   PubMed Web of Science ®Google Scholar
• de Benedictis FM, Teper A, Green RJ, et al. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch Pediatr Adolesc Med. 2001;155(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• Ferguson AC, van Bever HP, Teper AM, et al. A comparison of the relative growth velocities with budesonide and fluticasone propionate in children with asthma. Respir Med. 2007;101(1):118–129.
   PubMed Web of Science ®Google Scholar
• Ferguson AC, Spier S, Manjra A, et al. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134(4):422–427.
   PubMed Web of Science ®Google Scholar
• Fitzgerald D, Van Asperen P, Mellis C, et al. Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma. Thorax. 1998;53(8):656–661.
   PubMed Web of Science ®Google Scholar
• Gustafsson P, Tsanakas J, Gold M, et al. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Arch Dis Child. 1993;69(2):206–211.
   PubMed Web of Science ®Google Scholar
• Hoekx JC, Hedlin G, Pedersen W, et al. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(−1). Eur Respir J. 1996;9(11):2263–2272.
   PubMed Web of Science ®Google Scholar
• Kuo LY, Hung CH, Tseng HI, et al. Effects of budesonide and fluticasone propionate in pediatric asthma patients. Pediatr Neonatol. 2010;51(1):31–36.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Clark DJ, McFarlane LC. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax. 1997;52(8):686–689.
   PubMed Web of Science ®Google Scholar
• Pedersen S, Engelstatter R, Weber HJ, et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulm Pharmacol Ther. 2009;22(3):214–220.
   PubMed Web of Science ®Google Scholar
• Pedersen S, Garcia Garcia ML, Manjra A, et al. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol. 2006;41(10):954–961.
   PubMed Web of Science ®Google Scholar
• Rao R, Gregson RK, Jones AC, et al. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J. 1999;13(1):87–94.
   PubMed Web of Science ®Google Scholar
• Sherrington CA, Mallol J. Early effects of inhaled steroids on airway hyperreactivity and pulmonary function in asthma. Pediatr Pulmonol. 1999;27(6):376–382.
   PubMed Web of Science ®Google Scholar
• Wolthers OD, Pedersen S. Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child. 1993;68(5):673–676.
   PubMed Web of Science ®Google Scholar
• Yiallouros PK, Milner AD, Conway E, et al. Adrenal function and high dose inhaled corticosteroids for asthma. Arch Dis Child. 1997;76(5):405–410.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622–639.
   PubMed Web of Science ®Google Scholar
• Padden J, Skoner D, Hochhaus G. Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids. J Asthma. 2008;45(Suppl 1):13–24.
   PubMed Web of Science ®Google Scholar
• van der Velden VH. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm. 1998;7(4):229–237.
   PubMed Web of Science ®Google Scholar
• Doogue MP, Polasek TM. The ABCD of clinical pharmacokinetics. Ther Adv Drug Saf. 2013;4(1):5–7.
   PubMedGoogle Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380.
   PubMed Web of Science ®Google Scholar
• Falcoz C, Oliver R, McDowall JE, et al. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39(Suppl 1):9–15.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001;51(5):400–409.
   PubMed Web of Science ®Google Scholar
• Nave R, Bethke TD, van Marle SP, et al. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet. 2004;43(7):479–486.
   PubMed Web of Science ®Google Scholar
• Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl. 1982;122:86–95.
   PubMedGoogle Scholar
• Cerasoli F Jr. Developing the ideal inhaled corticosteroid. Chest. 2006;130(1 Suppl):54s–64s.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Harker AJ, Taylor S, et al. Plasma protein binding (PPB) of corticosteroids (CS): reappraisal of its significance in systemic pharmacological activity. J Allergy Clin Immunol. 2005;115(2, Supplement):S4.
   Google Scholar
• Budesonide. Micromedex® 2.0 (electronic version). Greenwood Village, Colorado, USA: Truven Health Analytics. [cited 2016 Dec 10]. Available from: http://www.micromedexsolutions.com.
   Google Scholar
• Beclomethasone dipropionate. Micromedex® 2.0 (electronic version). Greenwood Village, Colorado, USA: Truven Health Analytics. [cited 2016 Dec 10]. Available from: http://www.micromedexsolutions.com
   Google Scholar
• Fluticasone propionate. Micromedex® 2.0 (electronic version). Greenwood Village, Colorado, USA: Truven Health Analytics. [cited 2016 Dec 10]. Available from: http://www.micromedexsolutions.com.
   Google Scholar
• Ciclesonide. Micromedex® 2.0 (electronic version). Greenwood Village, Colorado, USA: Truven Health Analytics. [cited 2016 Dec 10]. Available from: http://www.micromedexsolutions.com
   Google Scholar
• Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am. 1999;5(4):537–553.
   PubMedGoogle Scholar
• Mackie AE, Ventresca GP, Fuller RW, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996;41(6):539–542.
   PubMed Web of Science ®Google Scholar
• Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3(1):53–72.
   PubMedGoogle Scholar
• Rohatagi S, Rhodes GR, Chaikin P. Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids. J Clin Pharmacol. 1999;39(7):661–663.
   PubMed Web of Science ®Google Scholar
• Su MX, Song M, Zhuang Y, et al. Simultaneous determination of ciclesonide and its active metabolite desisobutyryl-ciclesonide in human plasma by LC-APCI-MS/MS: application to pharmacokinetic study in healthy Chinese volunteers. J Pharm Biomed Anal. 2011;55(1):230–235.
   PubMed Web of Science ®Google Scholar
• Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007;73(10):1657–1664.
   PubMed Web of Science ®Google Scholar
• El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med. 2017;17(1):31.
   PubMed Web of Science ®Google Scholar